CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present new results from ongoing clinical studies with two of its subcutaneously administered investigational RNAi therapeutics – ALN-AT3 and ALN-CC5 – at the 57th Annual Meeting of the American Society of Hematology (ASH) being held December 5-8, 2015 in Orlando, Florida.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
